Vitamin C tablets

País: Armênia

Língua: inglês

Origem: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredientes ativos:

ascorbic acid

Disponível em:

Arpimed LLC

Código ATC:

A11GA01

DCI (Denominação Comum Internacional):

ascorbic acid

Dosagem:

500mg

Forma farmacêutica:

tablets

Unidades em pacote:

(20) in plastic container

Tipo de prescrição:

OTC

Status de autorização:

Registered

Data de autorização:

2022-07-26

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Vitamin C 250 mg tablets
Vitamin C 500 mg tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 250mg of ascorbic acid.
Each tablet contains 500mg of ascorbic acid.
For excipients, see 6.1.
3. PHARMACEUTICAL FORM
Tablet
250mg tablets: round biconvex white tablets scored on one side;
without odor
500mg tablets:
slightly violet round biconvex tablets of white color;
without odor
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Prevention and treatment of scurvy.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Route of administration:
Oral
Dose
Adults (including the elderly) and children over 6 years:
_ _
_Prophylactic:_ 25 – 75 mg daily.
Note: Thеsе unit dosages forms аre unsuitable for prophylactic use.
_Therapeutic: _Not less than 250mg daily in divided doses.
Maximum of
1000mg daily.
Children under 6 years:
These unit dosage forms are unsuitable for children under 6 years.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
Ascorbic acid should not be given to patients with hyperoxaluria.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Increased intake of ascorbic acid over a prolonged period may result
in an increase in renal
clearance of ascorbic acid and deficiency may result if it is
withdrawn rapidly (see section 4.8).
Interference with serological testing
Ascorbic acid may interfere with tests and assays for urinary glucose,
giving false-negative
results with methods utilising glucose oxidase with indicator (e.g.
Labstix, Tes-Tape) and false-
positive results with neocuproine methods.
Estimation of uric acid by phosphotungstate or uricase with copper
reduction and measurement
of creatinine in non-deproteinised serum may also be affected.
High doses of ascorbic acid may give false-negative readings in faecal
occult blood tests.
Patients with rare hereditary problems of galactose intolerance, total
lactase deficiency or
glucose-galactose malabsorption should not